Oxford Immunotec Global PLC (NASDAQ:OXFD)’s share price reached a new 52-week low during trading on Wednesday . The company traded as low as $8.31 and last traded at $8.89, with a volume of 18,433 shares traded. The stock had previously closed at $8.86.

A number of equities analysts have recently commented on OXFD shares. Piper Jaffray Cos. reissued a “buy” rating on shares of Oxford Immunotec Global PLC in a report on Sunday, June 26th. BTIG Research reissued a “buy” rating and set a $17.00 price target on shares of Oxford Immunotec Global PLC in a report on Monday, June 27th. Finally, Zacks Investment Research cut Oxford Immunotec Global PLC from a “buy” rating to a “hold” rating in a report on Wednesday.

The company has a 50-day moving average price of $9.02 and a 200-day moving average price of $10.10. The firm’s market capitalization is $200.61 million.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last announced its quarterly earnings results on Tuesday, May 3rd. The company reported ($0.32) EPS for the quarter, hitting the consensus estimate of ($0.32). The company earned $17.10 million during the quarter, compared to analysts’ expectations of $16.96 million. During the same quarter in the previous year, the firm earned ($0.31) EPS. The firm’s revenue for the quarter was up 23.9% compared to the same quarter last year. Equities analysts expect that Oxford Immunotec Global PLC will post ($1.25) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Oxford Immunotec Global PLC stock. OppenheimerFunds Inc. increased its stake in Oxford Immunotec Global PLC (NASDAQ:OXFD) by 0.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,068,967 shares of the company’s stock after buying an additional 5,440 shares during the period. OppenheimerFunds Inc. owned about 4.74% of Oxford Immunotec Global PLC worth $12,293,000 at the end of the most recent quarter.

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.